Pulido N, Casla A, Suárez A, Casanova B, Arrieta F J, Rovira A
Department of Endocrinology, Universidad Autónoma de Madrid, Spain.
Diabetologia. 1996 Jan;39(1):22-7. doi: 10.1007/BF00400409.
We studied the effect of gliclazide, a second-generation sulphonylurea, on rat skeletal muscle glucose uptake using perfused hindquarter muscle preparations. Gliclazide at concentrations of 10 to 1000 microgram/ml increased (p < 0.05) the basal glucose uptake. The effect of gliclazide on glucose uptake was immediate and dose-dependent, reaching a plateau at a concentration of 300 micrograms/ml; the half-maximal effect was obtained between 25 and 50 micrograms/ml. The glucose uptake stimulated by gliclazide (300-1000 micrograms/ml) did not differ from that achieved by 10(-9) mol/l insulin, and was lower (p < 0.05) than that obtained with 10(-7) mol/l insulin. The combination of gliclazide (300 micrograms/ml) and 10(-9) mol/l insulin produced an increase in glucose uptake (7.7 +/- 0.6 mumol.g-1.h-1, n = 8, mean +/- SEM) which was higher (p < 0.05) than that achieved with 10(-9) mol/l insulin (5.6 +/- 0.7 mumol.g-1.h-1, n = 11) and not different from that obtained with 10(-7) mol/l insulin (9.8 +/- 1.0 mumol.g-1.h-1, n = 11). Diazoxide (100 mumol/l), an ATP-sensitive K+ channel opener, reversed the stimulatory effect of gliclazide (100 microgram/ml) on muscle glucose uptake from 3.1 +/- 0.4 to 0.5 +/- 0.2 mumol.g-1.h-1, (n = 7, p < 0.001). The addition of diazoxide prior to gliclazide into the perfusion medium blocked the gliclazide-induced glucose uptake by the hindquarter muscle preparations. In conclusion, gliclazide alone has an immediate stimulatory effect on glucose uptake by skeletal muscle and together with insulin has an additive effect on muscle glucose uptake. The effect of gliclazide on muscle glucose uptake seems to be due to the inhibition of ATP-sensitive K+ channels.
我们使用灌注后肢肌肉制剂研究了第二代磺酰脲类药物格列齐特对大鼠骨骼肌葡萄糖摄取的影响。浓度为10至1000微克/毫升的格列齐特可增加(p < 0.05)基础葡萄糖摄取。格列齐特对葡萄糖摄取的作用迅速且呈剂量依赖性,在浓度为300微克/毫升时达到平台期;半数最大效应在25至50微克/毫升之间获得。格列齐特(300 - 1000微克/毫升)刺激的葡萄糖摄取与10⁻⁹摩尔/升胰岛素所达到的摄取量无差异,且低于(p < 0.05)10⁻⁷摩尔/升胰岛素所获得的摄取量。格列齐特(300微克/毫升)与10⁻⁹摩尔/升胰岛素联合使用可使葡萄糖摄取增加(7.7 ± 0.6微摩尔·克⁻¹·小时⁻¹,n = 8,平均值 ± 标准误),这高于(p < 0.05)10⁻⁹摩尔/升胰岛素所达到的摄取量(5.6 ± 0.7微摩尔·克⁻¹·小时⁻¹,n = 11),且与10⁻⁷摩尔/升胰岛素所获得的摄取量(9.8 ± 1.0微摩尔·克⁻¹·小时⁻¹,n = 11)无差异。二氮嗪(100微摩尔/升),一种ATP敏感性钾通道开放剂,可使格列齐特(100微克/毫升)对肌肉葡萄糖摄取的刺激作用从3.1 ± 0.4降至0.5 ± 0.2微摩尔·克⁻¹·小时⁻¹,(n = 7,p < 0.001)。在格列齐特加入灌注培养基之前先加入二氮嗪可阻断后肢肌肉制剂中格列齐特诱导的葡萄糖摄取。总之,单独使用格列齐特对骨骼肌葡萄糖摄取有直接刺激作用,与胰岛素联合使用对肌肉葡萄糖摄取有相加作用。格列齐特对肌肉葡萄糖摄取的作用似乎是由于对ATP敏感性钾通道的抑制。